問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Chi Mei Hospital, Liouying (在職)

Division of Hematology & Oncology

Division of Urology

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of General Surgery

National Health Research Institutes (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

陳尚鴻Chen, Shang-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -3 個月

Recruiting Trial

87Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳尚鴻

List

153Cases

2010-09-01 - 2013-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2009-06-01 - 2012-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-06-01 - 2011-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-09-01 - 2017-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-09-01 - 2018-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Suspended3Sites

2014-03-15 - 2017-12-31

Phase II

A PHASE 2, RANDOMIZED, OPEN LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACODYNAMICS, PHARMACOKINETICS OF THE ANTI-ALK-1 MAB PF-03446962 IN COMBINATION WITH BEST SUPPORTIVE CARE VS. BEST SUPPORTIVE CARE ALONE IN ADULT PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    PF-03446962 injection

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2006-11-20 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2018-03-05 - 2021-11-21

Phase I

An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours

  • Condition/Disease

    Advanced solid tumor

  • Test Drug

    BI 754091/BI 754111

Participate Sites
6Sites

Terminated6Sites

2021-10-21 - 2022-11-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

1 12 13 14 15 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB